A phase II, double-blind, placebo-controlled clinical trial to assess celecoxib as a chemopreventive agent inhibiting UV-induced erythema and cutaneous carcinogenesis as assessed through surrogate biological markers in biopsied skin after exposure of skin in normal volunteers ages 20-60 years old with Fitzpatrick type I, II, III and IV skin to UV-radiation from artificial light sources
Latest Information Update: 25 Mar 2013
At a glance
- Drugs Celecoxib (Primary)
- Indications Skin cancer
- Focus Therapeutic Use
- 20 Dec 2006 Status change
- 26 Aug 2005 New trial record.